Hardik Shah
2026.05.20 00:57

๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: FDA Accepts $ImmunityBio(IBRX.US) ImmunityBioโ€™s ANKTIVA Label Expansion Application

๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:

โžค FDA accepts ImmunityBioโ€™s ๐ฌ๐ฎ๐ฉ๐ฉ๐ฅ๐ž๐ฆ๐ž๐ง๐ญ๐š๐ฅ ๐๐‹๐€ for ANKTIVA plus BCG.

โžค Filing targets ๐๐‚๐†-๐ฎ๐ง๐ซ๐ž๐ฌ๐ฉ๐จ๐ง๐ฌ๐ข๐ฏ๐ž bladder cancer with papillary disease.

โžค FDA assigns ๐‰๐š๐ง. ๐Ÿ”, ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ• target action date.

โžค Expansion seeks inclusion of patients without ๐œ๐š๐ซ๐œ๐ข๐ง๐จ๐ฆ๐š ๐ข๐ง ๐ฌ๐ข๐ญ๐ฎ.

โžค QUILT 3.032 trial showed ๐Ÿ“๐Ÿ–.๐Ÿ% 12-month disease-free survival rate.

โžค Approximately ๐Ÿ–๐Ÿ“% of NMIBC patients present with ๐ฉ๐š๐ฉ๐ข๐ฅ๐ฅ๐š๐ซ๐ฒ ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž.

โžค Safety profile remained consistent with ๐๐‚๐† ๐š๐ฅ๐จ๐ง๐ž, company says

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

ยฉ 2026 Longbridge๏ฝœDisclaimer